Silvestre-Roig, Carlos
Braster, Quinte
Ortega-Gomez, Almudena
Soehnlein, Oliver http://orcid.org/0000-0002-7854-0694
Article History
Accepted: 4 December 2019
First Online: 29 January 2020
Competing interests
: C.S.-R. holds a patent on targeting histones in cardiovascular inflammation. O.S. has consulted for Novo Nordisk and AstraZeneca, has received a grant from Novo Nordisk to study the effect of circadian rhythms on atherosclerosis and holds a patent on targeting histones in cardiovascular inflammation. Q.B. and A.O.-G declare no competing interests.